Description: Boryung Corporation produces and sells pharmaceutical products in South Korea. The company offers cardiovascular products, anticancer products, gastrointestinal products, and API's. It also exports its products to approximately 50 countries on 6 continents, including Japan, China, the Southeast Asia, the Middle East, Europe, South America, and Africa. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is based in Seoul, South Korea.
Home Page: www.boryung.co.kr
136, Changgyeonggung-ro
Seoul,
03127
South Korea
Phone:
82 2 708 8000
Officers
| Name | Title |
|---|---|
| Mr. Jay Kim | Chairman & CEO |
| Young-Ha Kim | Sr. Managing Director, Director of Marketing Division and Director |
| Yong-Kwan Jeon | Head of R&D Center and Vice-Pres |
| Han-Woo Lee | Sr. Managing Director and Director of Overseas Bus. Division |
| Je-Hak Kim | Head of Central Research Center and Deputy Managing Director |
| Ji-Han Kim | Chief of Synthetic Research Center and Deputy Managing Director |
| Ho-Young Baek | Director of Operation Support Division and Director |
| Daniel Chang | Chief Exec. Officer of Pharma Biz |
| Yong-Bin Kim | Director of Production Division and Deputy Managing Director |
Exchange: KO
Country: KR
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4312 |
| Price-to-Sales TTM: | 0.991 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1335 |